Search

Your search keyword '"Nevelsteen I"' showing total 158 results

Search Constraints

Start Over You searched for: Author "Nevelsteen I" Remove constraint Author: "Nevelsteen I"
158 results on '"Nevelsteen I"'

Search Results

1. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

4. 52P Clinical characterization of HER2 low in patients with lobular breast cancer (ILC)

5. 14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status

7. P272 Manual lymph drainage does not substantially improve the effect of decongestive lymphatic therapy in people with breast cancer-related lymphoedema (EFforT-BCRL trial): a multicentre randomised trial

8. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

9. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

10. Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”: [Annals of Oncology 33 (2022) 769–785, (S092375342201167X), (10.1016/j.annonc.2022.05.006)]

11. Obesity-associated changes in molecular biology of primary breast cancer.

12. Changes in leukoencephalopathy and serum neurofilament after (neo) adjuvant chemotherapy for breast cancer

13. Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”

14. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in similar to 200,000 patients (vol 24, 69, 2022)

15. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

16. Serum methylmalonic acid concentrations at breast cancer diagnosis are not associated with distant metastases

17. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ∼200,000 patients

18. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study

19. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ∼ 200,000 patients (vol 24, 69, 2022)

20. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

21. 51P The development of a predictive model for risk results of the 70-gene signature

22. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

23. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

24. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

29. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

30. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

31. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

33. Abstract P1-15-04: Breast cancer recurrence and predictors for recurrence despite pathologic complete response following neoadjuvant chemotherapy

34. Abstract P4-02-07: Comparison of breast cancer molecular subtyping by Immunohistochemistry and by BluePrint® next generation RNA sequencing-based test at University Hospitals Leuven and Curie Institute Paris

35. Abstract P3-08-20: Clinical next-generation sequencing analysis in ER-positive HER2-negative metastatic breast cancer patients: Mutation frequency & clinical correlations

37. Abstract P5-09-05: Hereditary breast cancer beyond BRCA: Clinical and histopathological characteristics in patients with germline CHEK2, ATM, PALB2 and TP53-mutations

38. Abstract P3-03-32: Monocentric experience with the sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically lymph node negative early breast cancer

39. Abstract P4-08-25: Decentralized beta testing of MammaPrint and BluePrint NGS kit at University Hospitals Leuven and Curie Institute Paris

41. Genetic testing for breast cancer: Optimizing care for patients and their healthcare workers Development of a theoretical framework

43. Efficacy of CDK 4/6 inhibition after fulvestrant in metastatic breast cancer

45. Breast cancer subtype and survival by parity and time since last birth

48. Abstract P6-09-32: The association of breast cancer subtype and breast cancer survival with parity and time since last birth

50. SNP-SNP interaction analysis of NF-kappa B signaling pathway on breast cancer survival

Catalog

Books, media, physical & digital resources